Study Title: Randomized Study comparing Human Corticotropin-Releasing Factor to Placebo for Patients Requiring High-dose Dexamethasone
Category: Cancer, General
Currently accepting participants?
Not at this time.
Principal Investigator: Lynne Taylor MD
Study Coordinator: Gail Chumbley
Phone: 206-223-6835
Email: gchumbley@benaroyaresearch.org
What is the Randomized Study comparing Human Corticotropin-Releasing Factor to Placebo for Patients Requiring High-dose Dexamethasone study?
Patients in both groups will have brain tumors that are causing swelling in the brain and are taking Decadron to control their symptoms. One group of people will receive XERECEPT®. The other group of people will receive a placebo.
Who can participate?
Subjects must be 18 years or older and require the administration of at lest 4mg of Dexamethasone per day for control of brain edema symptoms.
Study Summary:
The purpose of this study is to examine the safety and efficacy of XERECEPT® compared to Decadron® for patients who require long-term high doses of Decadron to control the symptoms of brain swelling (edema).
Detailed Study Description:
Study Design: Blinded
Phase of Study: Phase III
Study Type: Interventional
Condition or Study Focus: Peritumoral Brain Edema
Intervention Type: Drug
Intervention Name: Xerecept: Human Corticotropin-Releasing Factor (hCRF)
Gender: Male and Female
Age group: Interventional
Sponsor: Celtic Pharma
Other studies in this category include:
Studies currently accepting study participants:
Studies currently not accepting study participants:
- A Randomized Phase III Trial of Concurrent Accelerated Radiation and Cisplatin Versus Concurrent Accelerated Radiation, Cisplatin, and Cetuximab (C225) Followed by Surgery for Selected Patients for Stage III and IV Head and Neck Carcinomas
- AMC045: HIV-Associated Anal Cancer
- Investigating Proteomic Biomarkers of Radiation Therapy Outcome: A Pilot Study
- Investigational drug vs. Placebo for Patients with Renal Cell Carcinoma (Kidney Cancer) at High Risk of Recurrence after Surgery
- Kidney Cancer (Renal Cell Carcinoma): Study Comparing Bevacizumab + Temsirolimus Vs Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects (INTORACT)
- Liver Cancer (Hepatocellular Carcinoma): Sorafenib vs Placebo as Adjuvant Treatment
- Liver Cancer (Hepatocellular Carcinoma): Study Of Sunitinib Malate Versus Sorafenib In Patients With Inoperable (Advanced or Metastatic) Liver Cancer
- Liver Cancer (Hepatocellular Carcinoma): TACE for Intermediate Stage
- MK0646 for Patients with Advanced Cancer
- Newly diagnosed, untreated ovarian or peritoneal cancer (GOG 0218)
- Radiation Therapy and Either Capecitabine or Fluorouracil With or Without Oxaliplatin Before Surgery in Treating Patients With Resectable Rectal Cancer
- Sorafenib v. Sunitinib v. Placebo for High Risk Renal Cell Carcinoma Patients
- Trial of FOLFOX with or without cetuximab for colon cancer
- Use of Human Corticotropin-Releasing Factor (hCRF) to Control Brain Swelling (edema) in Brain Tumor Patients
- Weekly IV of Hymcamtin in Combination with Carboplatin as Second Line Therapy in Potentially Platinum-Sensitive Reaplased Ovarian Cancer